However, recent research progress has shown that the combination of anti–programmed cell death-1 (PD-1) antibodies and anti-angiogenic drugs may become a potential first-line therapy for HCC (Ren et al., 2021). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.